<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278885</url>
  </required_header>
  <id_info>
    <org_study_id>DEALZ-2019-01</org_study_id>
    <nct_id>NCT04278885</nct_id>
  </id_info>
  <brief_title>Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)</brief_title>
  <acronym>LANA-FXII</acronym>
  <official_title>Factor XII-associated Cold Autoinflammatory Syndrome (FACAS) Linked to Kallikrein-kinin Pathology: Proof of Concept Treatment With Lanadelumab (DX-2930)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire International GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, exploratory, proof-of-concept, single-center, open-label pilot study to&#xD;
      assess the effects and safety of Lanadelumab in patients with FXII-associated cold&#xD;
      autoinflammatory syndrome (FACAS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Factor XII is a serine protease with diverse functions that participates in coagulation,&#xD;
      fibrinolysis, complement and contact system activation. So far, mutations in the factor XII&#xD;
      gene were linked to the rare coagulation disorder Hagemann factor deficiency and hereditary&#xD;
      angioedema (FXII-HAE).&#xD;
&#xD;
      The investigators recently identified a novel FXII mutation in a 4-generation family with&#xD;
      profound contact system activation and an autoinflammatory clinical phenotype.&#xD;
&#xD;
      Lanadelumab is a specific kallikrein Inhibitor that is known to prevent clinical symptoms and&#xD;
      contact system activation in hereditary angioedema.&#xD;
&#xD;
      This study aims at assessing the clinical effects and safety of Lanadelumab in patients with&#xD;
      FXII-associated cold autoinflammatory syndrome (FACAS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>exploratory, proof-of-concept, single-center, open-label pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported total disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF) grading the severity of 5 key symptoms of FACAS: urticarial rash, fatigue, chills/fever, arthralgia and headache (scale 0=no symptoms to 50=max. of symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in urticarial rash disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported urticarial rash disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported fatigue disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chills/fever disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported chills/fever disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF;scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arthralgia disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported arthralgia disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in headache disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab treatment</measure>
    <time_frame>weeks 9 to 12 and weeks 24 to 28, each compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported headache disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 10=max. of symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total disease activity score as assessed by daily health assessment form (DHAF) questionnaire following lanadelumab Treatment over Long-term use</measure>
    <time_frame>weeks 24 to 28 compared to weeks -4 to -1 (baseline)</time_frame>
    <description>Patient-reported total disease activity is assessed by a disease-specific daily health assessment form (FXII-associated Cold autoinflammatory Syndrome daily Health assessment form; FACAS-DHAF; scale 0=no symptoms to 50=max. of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Assessment of CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Assessment of ESR levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Assessment of SAA levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation markers following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Assessment of S100 A8/9 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dermatology-specific quality-of-life following lanadelumab Treatment</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>assessed by Dermatology Life Quality Index (DLQI); scale 0=no impairment to 30=max. impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in generic Health-related quality-of-life</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>assessed by 36-Item Short Form Health Survey (SF-36); scale 0=max. impairment to 100=no impairment (best Quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of of Treatment-emergent adverse Events, abnormal physical examination, abnormal Routine safety laboratory assessments, abnormal vital signs (safety and tolerability)</measure>
    <time_frame>from Baseline to end of study (week 36 follow-up)</time_frame>
    <description>Safety of lanadelumab Treatment is assessed by physical examination, routine safety laboratory assessments, vital signs, and adverse Event reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physician global assessment following lanadelumab Treatment as assessed by verbal rating scale</measure>
    <time_frame>from Baseline to week 12 and week 28</time_frame>
    <description>Verbal Rating scale assesses overall Symptoms from 0-10 (0=no symptoms; 10=very severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma levels of potential biomarkers following Lanadelumab treatment</measure>
    <time_frame>from Baseline to week 28</time_frame>
    <description>Potential biomarkers include Plasma FXII Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma levels of potential biomarkers following Lanadelumab treatment</measure>
    <time_frame>from Baseline to week 28</time_frame>
    <description>Potential biomarkers include Plasma prekallikrein Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma levels of potential biomarkers following Lanadelumab treatment</measure>
    <time_frame>from Baseline to week 28</time_frame>
    <description>Potential biomarkers include Plasma cHMWK Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma levels of potential biomarkers following Lanadelumab treatment</measure>
    <time_frame>from Baseline to week 28</time_frame>
    <description>Potential biomarkers include IL-1ÃŸ release from donor PBMCs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Hereditary Autoinflammatory Disease</condition>
  <arm_group>
    <arm_group_label>Lanadelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanadelumab</intervention_name>
    <description>300mg Lanadelumab s.c. administration every 2 weeks</description>
    <arm_group_label>Lanadelumab</arm_group_label>
    <other_name>DX-2930</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (18 years or older)&#xD;
&#xD;
          -  Documented FXII-associated autoinflammatory disorder (FACAS) by positive genetic&#xD;
             analysis result&#xD;
&#xD;
          -  Clinical symptoms of cold-associated wheals, arthralgia, headache, fatigue (FACAS)&#xD;
&#xD;
          -  Able to read, understand and willing to sign the informed consent form and abide with&#xD;
             study procedures&#xD;
&#xD;
          -  Males and females who are fertile and sexually active must adhere to contraception&#xD;
             requirements for the duration of the study as follows:&#xD;
&#xD;
          -  Females of childbearing potential must agree to be abstinent or else use any two of&#xD;
             the following medically acceptable forms of contraception from the screening period&#xD;
             through 30 days after the final study visit: progestin-only oral contraceptive, condom&#xD;
             with or without spermicidal jelly, diaphragm or cervical cap with spermicidal jelly,&#xD;
             or intra-uterine device (IUD, all types). Female participants whose male partner has&#xD;
             had a vasectomy must agree to use one additional form of medically acceptable&#xD;
             contraception.&#xD;
&#xD;
          -  Females of non-childbearing potential, defined as surgically sterile (status post&#xD;
             hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal&#xD;
             for at least 12 months do not require contraception during the study.&#xD;
&#xD;
          -  Males, including males who are surgically sterile (post vasectomy), with female&#xD;
             partners of childbearing potential must agree to be abstinent or else use a medically&#xD;
             acceptable form of contraception from the screening period through 60 days after the&#xD;
             last IMP injection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Any other forms of urticaria or angioedema not related to genetic mutations within&#xD;
             the FXII gene 2. Concurrent/ongoing treatment with biologics or recent treatment (less&#xD;
             than 5 half-lives) 3. Concurrent/ongoing treatment with anakinra within 7 days prior&#xD;
             to screening, with canakinumab within 100 days prior to screening 4.&#xD;
             Concurrent/ongoing treatment with oral/parenteral corticosteroids greater than 10 mg/d&#xD;
             within 2 weeks prior to screening 5. Concurrent/ongoing treatment with other&#xD;
             immunosuppressives within 4 weeks or 5 half-lives prior to screening, whichever is&#xD;
             longer 6. Treatment with a live (attenuated) virus vaccine within 4 weeks prior to&#xD;
             Baseline visit 7. Exposure to angiotensin-converting enzyme (ACE) inhibitors or any&#xD;
             estrogen-containing medications with systemic absorption (such as oral contraceptives&#xD;
             or hormonal replacement therapy) within 4 weeks prior to screening.&#xD;
&#xD;
             8. Use of prophylactic therapy with C1-INH, attenuated androgens, or antifibrinolytics&#xD;
             within 2 weeks prior to the start of the treatment period (Day 0).&#xD;
&#xD;
             9. Any of the following liver function test abnormalities:&#xD;
&#xD;
               -  alanine aminotransferase (ALT) &gt; 3x upper limit of normal, or&#xD;
&#xD;
               -  aspartate aminotransferase (AST) &gt; 3x upper limit of normal, or&#xD;
&#xD;
               -  total bilirubin &gt; 2x upper limit of normal (unless the bilirubin elevation is a&#xD;
                  result of Gilbert's Syndrome).&#xD;
&#xD;
                  10. Pregnancy or breastfeeding. 11. Subject has any condition that, in the&#xD;
                  opinion of the Investigator or Sponsor, may compromise their safety or&#xD;
                  compliance, preclude successful conduct of the study, or interfere with&#xD;
                  interpretation of the results (e.g., history of substance abuse or dependence, a&#xD;
                  significant pre-existing illness or other major comorbidity that the Investigator&#xD;
                  considers may confound the interpretation of study results).&#xD;
&#xD;
                  12. Significant medical condition rendering the patient immunocompromised or not&#xD;
                  suitable for a clinical trial.&#xD;
&#xD;
                  13. Enrollment in another investigational treatment or device study or use of an&#xD;
                  investigational agent, or less than 4 weeks or 5 half-lives, whichever is longer,&#xD;
                  since end of another investigational device or drug trial.&#xD;
&#xD;
                  14. Patients with known hypersensitivity to any constituent of the products of&#xD;
                  lanadelumab.&#xD;
&#xD;
                  15. Dementia, altered mental status, or any psychiatric condition, or stay in an&#xD;
                  institution further to an official or court order that would prohibit the&#xD;
                  understanding or rendering of informed consent or participation in the study.&#xD;
&#xD;
                  16. Subjects who are study site employees, or immediate family members of a study&#xD;
                  site or sponsor employee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karoline Krause, PD Dr. med.</last_name>
    <phone>+4930450518336</phone>
    <email>karoline.krause@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite University, Berlin, Germany</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krause Karoline, PD Dr. med.</last_name>
      <phone>004930450518336</phone>
      <email>karoline.krause@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Karoline Krause</investigator_full_name>
    <investigator_title>Ass. Professor</investigator_title>
  </responsible_party>
  <keyword>FXII-associated cold autoinflammatory syndrome (FACAS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
    <mesh_term>Familial Mediterranean Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

